1-氨基-1-[(4-甲基苯基)甲基]脲,甲磺酸 | 425675-45-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-氨基-1-[(4-甲基苯基)甲基]脲,甲磺酸
• 英文名称: 1-[(4-methylphenyl)methyl]hydrazinecarboxamide monomethanesulfonate
• 英文别名: 1-(4-methylphenylmethyl)hydrazinecarboxamide methanesulfonate；1-amino-1-[(4-methylphenyl)methyl]urea;methanesulfonic acid
• CAS: 425675-45-2
• 化学式: CH₄O₃S*C₉H₁₃N₃O
• 分子量: 275.329
• InChiKey: SPZGBPGLGSRRNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.25
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  135
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-氨基-1-[(4-甲基苯基)甲基]脲,甲磺酸 在 吡啶 、 camphor-10-sulfonic acid 、 sodium hydroxide 作用下， 以 水 、 乙酸乙酯 、 甲苯 为溶剂， 反应 13.0h， 生成 2-[4-[3-[2,5-二氢-1-[(4-甲基苯基)甲基]-5-氧代-1H-1,2,4-T噻唑-3-基]丙基]苯氧基]-2-甲基-丙酸
  参考文献：
  名称：

  PPARα激动剂LY518674的收敛千克级合成：新型酸介导的三唑酮合成的发现

  摘要：

  描述了PPARα激动剂LY518674（1）的第一公斤级合成。从头聚合方法包括偶联两个快速组装的组分，通过新型的酸促进的环化反应形成三唑酮和最后一步皂化，通过八步共六步最长的线性顺序，以32.5％的总收率递送该化合物。在4-羟基苯基丁酸的二价阴离子上进行区域选择性烷基化，可以直接制备会聚偶联伙伴之一的羧酸12，并且非常规的溶剂作用使脲基可以在受保护的肼上安装，从而可以对苯二酚进行区域特异性制备。其他偶合剂，甲磺酸氨基脲17。发现磺酸以实现所需的三唑酮环的形成，得到25从耦合前体酰基氨基脲23。以下的皂化25至1，乙酸乙酯提取物之间的宽溶解性差异1和溶液1于无水乙酸乙酯在最后结晶步骤以提供高收率和高纯度的最终化合物利用。在一系列其他底物上进一步评估了新型酸介导的三唑酮的形成，显示出该新方法与现有的碱介导的三唑酮合成在很大程度上互补。

  DOI：

  10.1021/op700040v
• 作为产物：
  描述：

  2-(aminocarbonyl)-2-[(4-methylphenyl)methyl]hydrazinecarboxylic acid, 1,1-dimethylethyl ester 以98.6的产率得到1-氨基-1-[(4-甲基苯基)甲基]脲,甲磺酸
  参考文献：
  名称：

  Organic Process Research & Development 2007, 11, 431-440

  摘要：

  DOI：

文献信息

• The synthesis of three isotopomers of 2-methyl-2-(4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]propyl]phenoxy)propionic acid, a potent and selective peroxisome proliferator-activated receptor alpha agonist
  作者：Fengjiun Kuo、Dean K. Clodfelter、Nagy A. Farid、William J. Wheeler、Lennon H. McKendry

  DOI：10.1002/jlcr.1395

  日期：2007.7

  Although fenofibrate (1a) is commercially available and clinically effective in lowering serum triglycerides, its activity and sub-type selectivity at the PPARα receptors are only moderate; therefore, there exists a need for more potent and sub-type selective PPARα agonists. To that end, discovery efforts have identified 2-methyl-2-(4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]propyl]phenoxy)propionic acid (2), a potent and selective human PPARα receptor agonist. In support of pre-clinical ADME studies and bioanalysis, three isotopomers of 2 have been synthesized. The results of these efforts are described below. Copyright © 2007 John Wiley & Sons, Ltd.

  非诺贝特（1a）虽已上市并能有效地降低血清甘油三酯，其在过氧化物酶体增殖激活受体α（PPARα）上的活性和亚型选择性仅属中等水平；因此，需要更强效且更具亚型选择性的PPARα激动剂。为此，研发过程中发现了2-甲基-2-(4-[3-[1-(4-甲基苄基)-5-氧代-4,5-二氢-1H-[1,2,4]三唑-3-基]丙基]苯氧基)丙酸（化合物2），它是一种强效且选择性的人源PPARα受体激动剂。为了支持临床前ADME研究和生物分析，合成了化合物2的三种同位素标记物。以下将详细描述这些成果。版权所有 © 2007 John Wiley & Sons, Ltd.
• Peroxisome proliferator activated receptor alpha agonists
  申请人：——

  公开号：US20040102500A1

  公开（公告）日：2004-05-27

  The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C 1 -C 8 alkyl, aryl-C 0-2 -alkyl, heteroaryl-C 0-2 -alkyl, C 3 -C 6 cycloalkylaryl-C 0-2 -alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and heteroaryl. X is a C 2 -C 5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH 2 ) n COOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C 1 -C 5 alkyl, C 1 -C 5 alkoxy. Additionally, R4 is H, halo, a substituted or unsubstituted group selected from C 1 -C 5 alkyl, C 1 -C 5 alkoxy, C 3 -C 6 cycloalkyl, arylC 0 -C 4 alkyl and phenyl, or R3 and R4 are combined to form a C 3 -C 4 cycloalkyl.

  本发明涉及以下结构式所代表的化合物，以及其药用可接受的盐、溶剂化合物和水合物，其中R1是从C1-C8烷基、芳基-C0-2-烷基、杂环芳基-C0-2-烷基、C3-C6环烷基芳基-C0-2-烷基或苯基中选择的取代或未取代基团。W是O或S。R2是H或从C1-C6烷基、C3-C6环烷基和杂环芳基中选择的取代或未取代基团。X是一个C2-C5烷基亚甲基连接物，其中连接物的一个碳原子可以被O、NH或S取代。Y是C、O、S、NH或一个单键。此外，E是(CH2)nCOOH，其中n为0、1、2或3，或C(R3)(R4)A，其中A是酸性官能团，如羧基、羧酰胺取代或未取代的磺酰胺，或取代或未取代的四唑。R3是H、饱和或不饱和的C1-C5烷基、C1-C5烷氧基。另外，R4是H、卤素、从C1-C5烷基、C1-C5烷氧基、C3-C6环烷基、芳基-C0-C4烷基和苯基中选择的取代或未取代基团，或者R3和R4组合形成一个C3-C4环烷基。
• PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS
  申请人：Cano Ivan Collado

  公开号：US20090062358A1

  公开（公告）日：2009-03-05

  The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C 1 -C 8 alkyl, aryl-C 0-2 -alkyl, heteroaryl-C 0-2 -alkyl, C3-C6 cycloalkylaryl-C 0-2 -alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl and heteroaryl. X is a C 2 -C 5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH 2 ) n COOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C 1 -C 5 alkyl, C 1 -C 5 alkoxy. Additionally, R4 is H, halo, a substituted or unsubstituted group selected from C 1 -C 5 alkyl, C 1 -C 5 alkoxy, C 3 -C 6 cycloalkyl, arylC 0 -C 4 alkyl and phenyl, or R3 and R4 are combined to form a C 3 -C 4 cycloalkyl.

  本发明涉及以下结构式所代表的化合物，以及其药学上可接受的盐、溶剂合物和水合物，其中，R1是C1-C8烷基、芳基-C0-2-烷基、杂芳基-C0-2-烷基、C3-C6环烷基芳基-C0-2-烷基或苯基的取代或未取代基团。W为O或S。R2为H或C1-C6烷基、C3-C6环烷基和杂芳基的取代或未取代基团。X为C2-C5烷基链，在链中的一个碳原子可以被O、NH或S取代。Y为C、O、S、NH或单键。此外，E为(CH2)nCOOH，其中n为0、1、2或3，或C(R3)(R4)A，其中A为酸性功能基团，如羧基、羧酰基取代或未取代的磺酰胺基、取代或未取代的四唑基。R3为H、饱和或不饱和的C1-C5烷基、C1-C5烷氧基。此外，R4为H、卤素、C1-C5烷基、C1-C5烷氧基、C3-C6环烷基、芳基C0-C4烷基和苯基的取代或未取代基团，或R3和R4结合形成C3-C4环烷基。
• [EN] PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONISTS<br/>[FR] AGONISTES DE RECEPTEURS ALPHA ACTIVES DE LA PROLIFERATION DES PEROXYSOMES
  申请人：LILLY CO ELI

  公开号：WO2002038553A2

  公开（公告）日：2002-05-16

  he present invention is directed to compounds represented by the following structural formula (I'), and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-2-alkyl, heteroaryl-C0-2-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C1-C6 alkyl, C3-C6 cycloalkyl and heteroaryl. X is a C2-C5 alkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH2)nCOOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C1-C5 alkyl, C1-C5 alkoxy. Additionally, R4 is H, halo, a substituted or unsubstituted group selected from C1-C5 alkyl, C1-C5 alkoxy, C3-C6 cycloalkyl, arylC0-C4alkyl and phenyl, or R3 and R4 are combined to form a C3-C4 cycloalkyl.

  本发明涉及如下所示结构式(I')表示的化合物及其药学上可接受的盐、溶剂化物和水合物。R1是自C1-C8烷基、C0-2烷基芳基、C0-2烷基杂芳基、C3-C6环烷基芳基-C0-2烷基或苯基中选择的取代或未取代基团。W是O或S。R2是H，或自C1-C6烷基、C3-C6环烷基和杂芳基中选择的取代或未取代基团。X是C2-C5亚烷基连接基团，其中连接基团的一个碳原子可被O、NH或S替换。Y是C、O、S、NH或单键。此外，E是(CH2)nCOOH，其中n=0、1、2或3，或C(R3)(R4)A，其中A为酸性功能基团，如羧基、羧酸酰胺、取代或未取代磺酰胺，或取代或未取代的四氮唑。R3是H、饱和或不饱和C1-C5烷基、C1-C5烷氧基。另外，R4是H、卤素、自C1-C5烷基、C1-C5烷氧基、C3-C6环烷基、C0-C4烷基芳基和苯基中选择的取代或未取代基团，或R3和R4结合形成C3-C4环烷基。
• The Role of New Technologies in Defining a Manufacturing Process for PPARα Agonist LY518674
  作者：Mark D. Argentine、Timothy M. Braden、Jeffrey Czarnik、Edward W. Conder、Steven E. Dunlap、Jared W. Fennell、Mark A. LaPack、Roger R. Rothhaar、R. Brian Scherer、Christopher R. Schmid、Jeffrey T. Vicenzi、Jeffrey G. Wei、John A. Werner、Robert T. Roginski

  DOI：10.1021/op8002486

  日期：2009.3.20

  The impact of several new technologies on the development of a manufacturing process for LV518674 is described. Extensive use of process analytical technology (PAT) throughout development, both at laboratory and pilot-plant scale, enabled data-rich experiments, shortened development cycle times, and obviated the requirement of PAT for process control at larger scale. In situ ReactIR was used to develop a kinetic model for a one-pot preparation of a semicarbazide intermediate. Parallel crystallizers fitted with online focused-beam reflectance measurement (FBRM) and particle vision and measurement (PVM) probes were used in the development of several challenging crystallization processes. Application of the process knowledge afforded by these technologies, combined with the principles of Quality by Design, resulted in excellent purity control throughout the four-step process. A single, 5-min, MS-friendly method capable of separating over 30 components was developed using a combination of chromatography modeling software, sub-2 mu m column technology, and higher-pressure LC equipment. The method was used across all four processing steps, greatly facilitating impurity tracking, and reducing assay time and solvent use by 85% and 93%, respectively.